Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000772840 | SCV000906222 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-11-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000772840 | SCV001171998 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-03-30 | criteria provided, single submitter | clinical testing | The p.P484S variant (also known as c.1450C>T), located in coding exon 12 of the CHEK2 gene, results from a C to T substitution at nucleotide position 1450. The proline at codon 484 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Invitae | RCV003607347 | SCV004389082 | uncertain significance | Familial cancer of breast | 2023-02-21 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 484 of the CHEK2 protein (p.Pro484Ser). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CHEK2-related conditions. ClinVar contains an entry for this variant (Variation ID: 628381). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |